Lamivudina Mylan (Lamivudine)

Lamivudine is a nucleoside analogue that, after conversion to its active triphosphate inside cells, competes with natural nucleotides for incorporation by viral reverse transcriptase or hepatitis B polymerase. Its incorporation halts the elongation of viral DNA, thereby suppressing replication of HIV and hepatitis B viruses.

The dosage of Lamivudina Mylan is individualized by the prescribing clinician based on the patient’s age, weight, renal function, co‑administered drugs, and the specific indication. Only a qualified healthcare professional can set the appropriate dose and regimen.

The safety of lamivudine in pregnancy and lactation has not been definitively established. It should only be used during pregnancy or while breastfeeding when the potential benefit justifies any potential risk, and this decision must be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Lamivudina Mylan. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Lamivudine belongs to the nucleoside reverse transcriptase inhibitor (NRTI) class, offering a favorable safety profile and convenient oral dosing. Compared with some older NRTIs, it has lower mitochondrial toxicity and is often combined with newer agents such as tenofovir or integrase inhibitors to achieve potent viral suppression.

Lamivudina Mylan should be stored at ambient temperature below 25 °C (77 °F). Keep the tablets in the original container, protect them from moisture and direct light, and ensure they are out of reach of children.

Lamivudina Mylan is administered orally, usually as a tablet taken with or without food. The exact dosing schedule, including frequency and duration, is determined by the prescribing clinician based on the patient’s clinical condition.

Serious risks, though uncommon, include lactic acidosis, severe hepatomegaly with steatosis, and severe skin reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. Patients should be monitored for signs of metabolic disturbance, liver enlargement, or skin changes and seek immediate medical attention if they occur.

Lamivudina Mylan should be avoided in individuals with a known hypersensitivity to lamivudine or any of its excipients. Caution is also advised for patients with severe hepatic impairment, mitochondrial disorders, or those receiving contraindicated drug combinations.